PFS and OS after Salvage Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors (GEP-NETs) – The Rotterdam Cohort

#2292

Introduction: PRRT with 177Lu-DOTATATE (LuTate) is effective in patients with metastatic or inoperable GEP-NETs.

Aim(s): The efficacy and toxicity of salvage PRRT was evaluated in a large group of GEP-NET patients with long follow-up.

Materials and methods: Patients were selected for salvage PRRT if they had benefited from initial PRRT and showed renewed progression. Benefit was defined as SD, PR or CR (RECIST 1.1). Salvage PRRT took place between 2003-2015, with follow-up until end 2016. Intended dose for salvage PRRT was 14.8GBq divided over 2 administrations. Total intended cumulative dose (cumdose) per patient for the initial treatment (I-PRRT) was 29.6GBq, for re-treatment (R-PRRT) 44.4GBq and for re-re-treatment (RR-PRRT) 59.2GBq.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: van der Zwan W

Authors: Van der Zwan W, Brabander T, Kam B, Teunissen J, Krenning E,

Keywords: Salvage, PRRT, Re-treatment, GEP-NET, Safety, Efficacy, 177Lu-DOTATATE,